Development Begins on Original Technology to Eliminate Antibiotic-Resistant Bacteria Using Microbiota
Seungsoon Lee's Team at Hallym University Chuncheon Sacred Heart Hospital
Selected for the "Core Research of Basic Individual Research Projects" by the Ministry of Science and ICT and the National Research Foundation of Korea
Receiving 1.5 B
Research aimed at controlling antibiotic-resistant bacteria, which are difficult to treat with antibiotics, using gut microbiota is set to begin in earnest.
Seungsoon Lee, Professor of Infectious Diseases at Hallym University Chuncheon Sacred Heart Hospital. Hallym University Chuncheon Sacred Heart Hospital
View original imageOn March 20, Hallym University Chuncheon Sacred Heart Hospital announced that the research team led by Professor Seungsoon Lee from the Department of Infectious Diseases has been selected for the "Core Research (Type C) of Basic Individual Research Projects," organized by the Ministry of Science and ICT and supported by the National Research Foundation of Korea. The research will be conducted over five years, from March 2026 to February 2031, with a total research grant of 1.5 billion won.
The objective of the project is to develop original technology to eliminate carbapenem-resistant Enterobacteriaceae (CRE) by leveraging the gut microbial ecosystem. CRE is a major antibiotic-resistant bacterium designated by the World Health Organization, known for its limited treatment options and high risk of spreading infections within hospitals.
The research team will apply a "Design-Test-Learn" structure that combines multi-omics analysis and artificial intelligence-based design. The core goal is to precisely analyze changes in the gut microbial ecosystem and host-microbiota interactions to elucidate the mechanisms of CRE colonization and removal.
In particular, the team plans to design function module-based symbiotic microbial consortia to establish strategies that selectively suppress resistant bacteria. This will be pursued as translational research that considers the feasibility of clinical application by integrating patient-derived clinical data with experimental validation.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Professor Lee stated, "Through this research, we aim to systematically identify the fundamental principles of new therapeutic strategies based on the functional characteristics of gut microbiota and deliver substantial research outcomes that will enhance the prospects for future clinical application."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.